1. Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel.
- Author
-
Halabi, Susan, Dutta, Sandipan, Tangen, Catherine M, Rosenthal, Mark, Petrylak, Daniel P, Thompson, Ian M, Chi, Kim N, Bono, Johann S De, Araujo, John C, Logothetis, Christopher, Eisenberger, Mario A, Quinn, David I, Fizazi, Karim, Morris, Michael J, Higano, Celestia S, Tannock, Ian F, Small, Eric J, and Kelly, William Kevin
- Subjects
PROSTATE cancer treatment ,CASTRATION-resistant prostate cancer ,DOCETAXEL ,PROSTATE cancer ,ASIANS ,WHITE men - Abstract
There are few data regarding disparities in overall survival (OS) between Asian and white men with metastatic castration-resistant prostate cancer (mCRPC). We compared OS of Asian and white mCRPC men treated in phase III clinical trials with docetaxel and prednisone (DP) or a DP-containing regimen. Individual participant data from 8820 men with mCRPC randomly assigned on nine phase III trials to receive DP or a DP-containing regimen were combined. Men enrolled in these trials had a diagnosis of prostate adenocarcinoma. The median overall survival was 18.8 months (95% confidence interval [CI] = 17.4 to 22.1 months) and 21.2 months (95% CI = 20.8 to 21.7 months) for Asian and white men, respectively. The pooled hazard ratio for death for Asian men compared with white men, adjusted for baseline prognostic factors, was 0.95 (95% CI = 0.84 to 1.09), indicating that Asian men were not at increased risk of death. This large analysis showed that Asian men did not have shorter OS duration than white men treated with docetaxel. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF